BioAge Labs, Inc. (NASDAQ:BIOA) Sees Large Growth in Short Interest

BioAge Labs, Inc. (NASDAQ:BIOA) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,744,445 shares, a growth of 87.9% from the June 15th total of 1,992,676 shares. Based on an average daily volume of 932,909 shares, the days-to-cover ratio is currently 4.0 days. Approximately 10.6% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Roth Capital began coverage on shares of BioAge Labs in a research report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price target on the stock. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Needham & Company LLC initiated coverage on BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Finally, BTIG Research started coverage on BioAge Labs in a report on Wednesday, May 13th. They set a “buy” rating and a $40.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.50.

BioAge Labs Price Performance

Shares of BIOA traded down $0.17 during mid-day trading on Thursday, hitting $22.53. The company’s stock had a trading volume of 28,768 shares, compared to its average volume of 610,100. The firm has a 50-day moving average price of $19.70 and a 200 day moving average price of $18.93. BioAge Labs has a fifty-two week low of $4.11 and a fifty-two week high of $25.95. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -9.37 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million during the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. As a group, equities analysts anticipate that BioAge Labs will post -2.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

A number of institutional investors and hedge funds have recently modified their holdings of BIOA. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs in the 3rd quarter valued at $27,000. CWM LLC boosted its holdings in shares of BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares during the period. Walleye Capital LLC purchased a new position in shares of BioAge Labs in the second quarter worth approximately $64,000. Finally, Bank of America Corp DE raised its holdings in shares of BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after acquiring an additional 3,517 shares during the period.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.